Online citations, reference lists, and bibliographies.
← Back to Search

Weakening Impact Of Excessive Human Serum Albumin (eHSA) On Cisplatin And Etoposide Anticancer Effect In C57BL/6 Mice With Tumor And In Human NSCLC A549 Cells

Z. Yang, Ting Zhou, Yuanchi Cheng, Mingming Li, Xianglin Tan, F. Xu
Published 2016 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Excessive human serum albumin (eHSA) impact on anticancer effects is inconsistent. We explored the outcome of cisplatin (DDP)/etoposide (VP-16) plus eHSA in vivo and in vitro. C57BL/6 mice with tumor were used to compare the efficacy of DDP/VP-16 alone and DDP/VP-16+eHSA. Blood albumin was measured to confirm whether eHSA elevate its level. Western blotting assay were used to measure the expression of ERCC1/TOP2A in tumor tissues. Cell proliferation, mRNA, and protein expression of ERCC1/TOP2A were also assayed to compare two groups in A549 cells. Furthermore we evaluated eHSA impact on cell proliferation in RNAi targeting ERCC1/TOP2A in A549 cells, respectively. eHSA reduced the anticancer effect of DDP/VP-16 without altering albumin level, increased protein expression of ERCC1/TOP2A, respectively in mice. Similarly, eHSA increased mRNA and proteins expression of ERCC1/TOP2A in A549 cells. In RNAi A549 cells, however, eHSA no longer weakened but enhanced the anticancer effect of DDP, while no longer altered the effect of VP-16. Our findings suggested that eHSA weaken the anticancer effect of DDP/VP-16 via up-regulating ERCC1/TOP2A expression, respectively. Further molecular mechanism studies are warranted to investigate whether eHSA is not conducive to lung cancer chemotherapy.
This paper references
10.1056/NEJMOA060570
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
K. Olaussen (2006)
10.1016/j.cbi.2016.02.009
Comparative analysis the binding affinity of mycophenolic sodium and meprednisone with human serum albumin: Insight by NMR relaxation data and docking simulation.
X. Ma (2016)
DNA repair by ERCC 1 in non - small - cell lung cancer and cisplatinbased adjuvant chemotherapy
K. A. Olaussen (2006)
10.1021/acs.jpcb.5b05998
A Comprehensive Computational Study of the Interaction between Human Serum Albumin and Fullerenes.
G. Leonis (2015)
Increased expression
J. He (2015)
10.1111/vec.12085
Type III hypersensitivity reaction with immune complex deposition in 2 critically ill dogs administered human serum albumin.
Cassandra Powell (2013)
10.1016/j.jphotobiol.2016.02.009
Interplay of multiple interaction forces: Binding of tyrosine kinase inhibitor nintedanib with human serum albumin.
P. Alam (2016)
10.1021/BI027293O
Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
P. Verdier-Pinard (2003)
10.1007/s13402-016-0291-7
The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells
P. Chen (2016)
10.1056/NEJMOA040232
A comparison of albumin and saline for fluid resuscitation in the intensive care unit.
S. Finfer (2004)
10.3322/caac.21166
Cancer statistics, 2013
R. Siegel (2013)
10.1007/978-1-4612-4174-4_17
Type III Hypersensitivity
E. M. Opremcak (1995)
Spectral characterization of the binding
R. 1111vec.12085 Punith (2012)
Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P 450 isoenzymes
X. Song (2011)
10.1016/j.lungcan.2011.01.016
Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.
X. Song (2011)
10.1016/j.ejpb.2016.01.017
Pharmaceutical formulation of HSA hybrid coated iron oxide nanoparticles for magnetic drug targeting.
J. Zaloga (2016)
10.1038/bjc.1980.103
Interaction of human serum albumin with anticancer agents in vitro.
I. Takahashi (1980)
10.2147/IJN.S24322
Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-folate-CDDP/HSA MNPs) in vivo
Qiu-sha Tang (2011)
Evaluation of the pattern of human albumin utilization at a university affiliated hospital.
A. H. Talasaz (2012)
A coreshell albumin copolymer nanotransporter for high capacity loading and two - step release of doxorubicin with enhanced antileukemia activity
Y. Wu (2013)
10.1016/j.saa.2012.02.038
Spectral characterization of the binding and conformational changes of serum albumins upon interaction with an anticancer drug, anastrozole.
R. Punith (2012)
10.1002/adhm.201200296
A core-shell albumin copolymer nanotransporter for high capacity loading and two-step release of doxorubicin with enhanced anti-leukemia activity.
Y. Wu (2013)
10.3322/canjclin.39.6.399
Cancer statistics
N. Dubrawsky (1989)
10.1007/BF00263529
Albumin abuse in intensive care medicine
A. Grootendorst (1988)
10.3109/10717549809065759
Serum proteins as drug carriers of anticancer agents: a review.
F. Kratz (1998)
10.1111/vec.12085
Type III hypersensitivity reaction with immune complex deposition in 2 critically ill dogs administered human serum albumin
Cassandra Powell Dvm (2013)
Review of the rational use
T. 1016j.ejpb.2016.01.017 Zhou (2013)
10.1039/c4mt00220b
Fortification of blood plasma from cancer patients with human serum albumin decreases the concentration of cisplatin-derived toxic hydrolysis products in vitro.
T. T. Morris (2014)
A comprehensive computational study
M. G. Papadopoulos (2015)
Adherence 7, 1207–1212
Patient Prefer (2016)
10.1016/0004-3702(88)90086-0
Comparative Analysis
Daniel S. Weld (1987)
10.1007/s12010-012-9733-5
The Anticancer Activity and HSA Binding Properties of the Structurally Related Platinum (II) Complexes
R. Yousefi (2012)
10.1007/978-0-387-39940-9_2232
Comparative Analysis
A. Conversi (2009)
10.1186/s13048-015-0207-6
MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1
Kai-xuan Sun (2015)
[Increased expression of acetaldehyde dehydrogenase in cisplatin-resistant human lung adenocarcinoma A549/DDP cells].
Jinxi He (2015)
10.2147/PPA.S53484
Review of the rational use and adverse reactions to human serum albumin in the People’s Republic of China
T. Zhou (2013)
[Rational use of albumin].
E. Sikuler (2000)
10.1002/14651858.CD001208.pub4
Human albumin solution for resuscitation and volume expansion in critically ill patients.
I. Roberts (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar